Part 2
Cancer Drug Program
5 Cancer drug program
6 Group 1 cancer drugs
7 Group 2 cancer drugs
8 Group 3 cancer drugs
9 Prescription
10 Drug
administration
Part 3
Investments
11 Investment of
money
Part 3.1
General
11.1 Health Care
Protection Act records
Part 4
Repeal, Expiry and Coming into Force
12 Repeal
13 Expiry
14 Coming into force
Interpretation
1(1) In this
Regulation,
(a) “board medical staff” means the physicians
appointed as members of the medical staff of the Cross Cancer Institute or the
Tom Baker Cancer Centre;
(b) “Board Pharmacy” means the pharmacy at the
Cross Cancer Institute and the Tom Baker Cancer Centre, a pharmacy established
by the board and a pharmacy that has a contract with the board to provide
pharmacy services;
(c) “Board Pharmacy and Therapeutics Committee”
means the Alberta Cancer Board Pharmacy and Therapeutics Committee;
(d) “cancer drug” means a drug that is specified
in the Schedule;
(e) repealed AR 19/2005 s2;
(f) “eligible member of the board medical staff”
means a member of the board medical staff who has been authorized by the
President or the President’s designate to review prescriptions for cancer drugs
and to prescribe cancer drugs;
(g) “eligible resident” means a person who
(i) is a resident of Alberta,
(ii) is registered in the Cancer Registry with a disease classified in
the International Classification of Diseases for Oncology referred to in
subsection (2),
(iii) holds an Alberta personal health number,
(iv) requires cancer drugs to treat cancer, and
(v) is an inpatient or outpatient of a cancer hospital, clinic or
program operated by the board;
(h) repealed AR 19/2005 s2;
(i) “President” means the chief executive
officer appointed pursuant to section 11 of the Act;
(j) “reportable cancer” means a cancer on the
list adopted under subsection (2);
(k) “Schedule”
means the schedule of cancer drugs established pursuant to section 16.1 of the
Act.
(2) The list of
all diseases in the International Classification of Diseases for Oncology,
as amended from time to time, published by the World Health Organization, is
adopted as the list of reportable cancers.
AR
242/98 s1;251/2001;19/2005
Part
1
Cancer Registry
Cancer
Registry
2(1) There
is hereby established the Cancer Registry.
(2) The board must register
the information referred to in sections 3 and 4 in the Cancer Registry.
Information from physicians
3 The following
information must be provided to the board under section 34(1) of the Act by a
physician who knows or has reason to believe that a patient under the
physician’s care or supervision has a reportable cancer:
(a) the following patient data:
(i) name, including last name, maiden name if
applicable and first name, and initials for any other names;
(ii) gender;
(iii) date of birth;
(iv) place of birth;
(v) Alberta personal health number;
(vi) patient’s address (including postal code) at
time of diagnosis;
(vii) vital status;
(viii) diagnosis;
(ix) date of diagnosis;
(x) method of diagnosis;
(xi) name and address of physician;
(xii) treatment (type and date) administered to
the patient;
(xiii) place, date and cause of death;
(b) the following tumour data:
(i) anatomical localization of the tumour;
(ii) morphology of the tumour;
(iii) histologic grade of tumour;
(iv) stage of the disease at diagnosis;
(v) site of metastasis, if appropriate;
(vi) laterality of tumour, if appropriate;
(vii) multi-focal tumour, if appropriate;
(viii) other critical prognostic variables, if
appropriate;
(ix) all clinical and epidemiological information
pertinent to the diagnosis and treatment.
AR
242/98 s3;251/2001;19/2005
Information from laboratories
4 The following
information must be provided to the board under section 34(2) of the Act by the
person responsible for the laboratory where an examination of a specimen from a
human body is conducted that reveals a reportable cancer:
(a) the following laboratory data:
(i) name of the laboratory;
(ii) address of the laboratory;
(b) the following patient data:
(i) name, including last name, maiden name if
applicable and first name, and initials for any other names;
(ii) address, if available;
(iii) Alberta personal health number;
(iv) date of test result (final report);
(c) the following site-specific tumour data:
(i) anatomical localization of the tumour;
(ii) morphology of the tumour;
(iii) histologic grade of tumour, if appropriate;
(iv) information relevant to staging, if
appropriate;
(v) site of metastasis, if appropriate;
(vi) laterality of tumour, if appropriate;
(vii) other critical prognostic variables, if
appropriate;
(viii) other information that the laboratory
considers appropriate.
AR
242/98 s4;251/2001
Part
2
Cancer Drug Program
Cancer
drug program
5 The
board may provide cancer drugs in the Schedule at no charge to eligible
residents for the treatment of cancer in accordance with this Part and the
Schedule.
AR
242/98 s5;19/2005
Group 1 cancer drugs
6(1) Cancer
drugs in group 1 of the Schedule may be provided by a Board Pharmacy pursuant
to a prescription written by a person who is authorized by the board to
prescribe cancer drugs and who is a physician, a regulated member under the Health
Professions Act authorized to prescribe drugs or a person authorized to
prescribe drugs pursuant to another enactment.
(2) Repealed AR 2/2006 s2.
AR
242/98 s6;19/2005;2/2006
Group 2 cancer drugs
7 Cancer drugs
in group 2 of the Schedule may be provided by a Board Pharmacy only if the
initial prescription is written by a member of the board medical staff, but a
subsequent prescription for the same patient may be written by a person
authorized by the board to prescribe cancer drugs and who is a physician, a
regulated member under the Health Professions Act authorized to
prescribe drugs or a person authorized to prescribe drugs pursuant to another
enactment.
AR
242/98 s7;19/2005
Group 3 cancer drugs
8 Cancer drugs in
group 3 of the Schedule may be provided by a Board Pharmacy if
(a) the cancer drugs are part of a research or
clinical drug trial approved by the board and the prescription is written by
the principal investigator or co-investigator in charge of the trial, or
(b) the cancer drugs are approved for special
access by Health Canada and a prescription is written by an eligible member of
the board medical staff.
AR
242/98 s8;19/2005
Prescription
9(1) A
prescription referred to in section 6, 7 or 8 must meet the requirements with
respect to the cancer drug set out in the column headed “criteria” in the
Schedule and must be in the dosage form set out in the Schedule.
(2) A prescription for a
cancer drug must include the Cancer Registry number issued by the board.
Drug administration
10 Subject to this
Regulation, cancer drugs may be
(a) administered
directly to patients of cancer hospitals, clinics or programs operated by the
board, or
(b) sent to other health care providers or Board
Pharmacies for administration or provision directly to the patient.
AR
242/98 s10;19/2005
Part
3
Investments
Investment
of money
11(1) When the
board makes investments it must adhere to investment and lending policies,
standards and procedures that a reasonable and prudent person would apply in
respect of a portfolio of investments to avoid undue risk of loss and obtain a
reasonable return.
(2) A contravention of
subsection (1) by the board does not of itself make any agreement or
transaction void or invalid.
Part
3.1
General
Health
Care Protection Act records
11.1(1) Subject to
subsection (2), the board shall keep a statement referred to in section 5(3) of
the Health Care Protection Act for a period of at least 10 years from
the date of discharge of the patient from the hospital.
(2) Where the patient was a
minor at the time the insured surgical service was provided, the board shall
keep the statement for a period ending
(a) 10 years after the date of discharge of the
patient from the hospital, or
(b) 2 years after the patient’s 18th birthday,
whichever
is longer.
(3) The board shall keep
for a period of 6 years after they are created all records, documents and books
of account that are necessary in order to determine whether the Health Care
Protection Act and the regulations under it have been complied with as they
apply with respect to the provision of enhanced medical goods or services and
non‑medical goods or services
(a) in connection with the provision of an
insured surgical service, or
(b) that arise out of a stay at a hospital
operated by the board.
(4) The board
may store statements, records, documents and books of account referred to in
this section in any format that will provide a copy of the statement, records,
document or book of account in a legible written form within a reasonable time.
AR
207/2000 s2
Part
4
Repeal, Expiry and
Coming into Force
Repeal
12 The Cancer
Regulations (AR 172/58) are repealed.
Expiry
13 For
the purpose of ensuring that this Regulation is reviewed for ongoing relevancy
and necessity, with the option that it may be repassed in its present or an
amended form following a review, this Regulation expires on September 30, 2014.
AR
242/98 s13;346/2003;19/2005
Coming into force
14 This Regulation
comes into force on the coming into force of the Cancer Programs Amendment
Act, 1992.
Schedule Repealed AR 19/2005 s10.
